BioSight Ltd, a pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, announced today that it has entered into a clinical trial agreement with the European Cooperative Group. The Study is expected to begin in Q4 2020.
Biosight Announces Clinical Trial Collaboration with the European Cooperative Group
![BioSight logo](http://ibf.fund/wp-content/uploads/2020/04/biosight-featured-image.png)